Increased detection of primary carnitine deficiency through second-tier newborn genetic screening

Yiming Lin1, Weifeng Zhang2, Chenggang Huang3, Chunmei Lin1, Weihua Lin1, Weilin Peng1, Qingliu Fu1* and Dongmei Chen2*

Abstract

Background: Newborn screening for primary carnitine deficiency (NBS) is commonly implemented worldwide; however, it has poor sensitivity. This study aimed to evaluate the feasibility of improving screening by including a second-tier genetic assay.

Results: An Agena iPLEX assay was developed to identify 17 common SLC22A5 mutations in Chinese populations and was applied in NBS as a second-tier screening. From January 2017 to December 2018, 204,777 newborns were screened for PCD using tandem mass spectrometry. A total of 316 (0.15%) residual NBS-positive specimens with low free carnitine (C0) levels were subjected to this second-tier screening. The screening identified 20 screen-positive newborns who harboured biallelic mutations in the SLC22A5 gene, 99 carriers with one mutation, and 197 screen-negative newborns with no mutations. Among the 99 carriers, four newborns were found to have a second-disease-causing SLC22A5 mutation by further genetic analysis. Among the 197 screen-negatives were four newborns with persistently low C0 levels, and further genetic analysis revealed that one newborn had two novel SLC22A5 pathogenic variants. In total, 25 newborns were diagnosed with PCD, for a positive predictive value of 7.91% (25/316). Based on these data, we estimate the incidence of PCD in Quanzhou is estimated to be 1:8191. Thirteen distinct SLC22A5 variants were identified, and the most common was c.760C > T, with an allelic frequency of 32% (16/50), followed by c.1400C > G (7/50, 14%), and c.51C > G (7/50, 14%).

Conclusion: Data from this study revealed that 24% (6/25) of PCD cases would have been missed by conventional NBS. This high-throughput iPLEX assay is a powerful tool for PCD genotyping. The addition of this second-tier genetic screening to the current NBS program could identify missed PCD cases, thereby increasing PCD detection. However, further studies are needed to optimise the workflow of the new screening algorithm and to evaluate the cost-effectiveness of this screening approach.

Keywords: Primary carnitine deficiency, Newborn screening, Free carnitine, Second-tier screening

Background

Primary carnitine deficiency (PCD, OMIM #212140) is an autosomal recessive disorder of fatty acid oxidation caused by biallelic mutations in the SLC22A5 gene, which encodes organic cation transporter type 2 (OCTN2) [1–3]. This defect leads to urinary carnitine wasting, low serum carnitine levels, and decreased intracellular carnitine accumulation. The clinical presentation of PCD...
is highly variable, ranging from no clinical symptoms to hypoketotic hypoglycaemia and hepatic encephalopathy early in life, progressive hypertrophic cardiomyopathy later in life, or even sudden death from cardiac arrhythmia [4–6]. Although some patients appear to be asymptomatic, PCD is a potentially lethal disease, and recent studies have shown that untreated PCD is associated with sudden death [7, 8]. Fortunately, with timely treatment, the long-term prognosis is favourable, as most symptoms are reversible [9].

Given the potential severity of PCD and the availability of effective treatment, PCD is included in many newborn screening (NBS) programs worldwide [10–12]. Tandem mass spectrometry (MS/MS) is mainly used in NBS for PCD, which can be detected by measuring free carnitine (C0) levels in a dried blood spot (DBS). However, the current MS/MS-based PCD NBS has poor sensitivity, leading to some neonates passing the NBS, yet presenting with cardiac failure and dilated cardiomyopathy due to PCD [13–17]. Recently, the New Zealand NBS program discontinued PCD NBS because of its low sensitivity [14]. Therefore, additional or second-tier testing is required to improve the performance of PCD NBS.

The Agena iPLEX assay is an effective and reliable approach for mutation screening, and our previous work demonstrated the feasibility of incorporating genetic screening into the current NBS program [18, 19]. Here, an Agena iPLEX PCD assay was developed to identify 17 common SLC22A5 mutations in the Chinese population, which was then applied as a second-tier test to improve the performance of PCD NBS. This study presents the results of the implementation of this new screening algorithm.

Results

Assay validation
A double-blind analysis of 20 PCD-positive DBS samples was conducted to validate the robustness of the iPLEX genotyping assay. The iPLEX assay correctly detected all SLC22A5 mutations in the 20 samples, indicating its high sensitivity and specificity (Table 1).

Newborn genetic screening and diagnosis
Overall, 316 (0.15%) of the 204,777 newborns screened via MS/MS at Quanzhou Maternity and Children’s Hospital had C0 low levels on the first screen and underwent second-tier genetic screening. The results of the second-tier testing identified 20 screen-positive newborns who harboured biallelic mutations in the SLC22A5 gene, 99 carriers with one mutation, and 197 screen-negative newborns with no mutations. Further genetic testing showed that 4 of the 99 carriers had a second SLC22A5 mutation. All 197 screen-negative newborns were retested using MS/MS, and four of them with persistently low C0 levels in this second screen underwent further genetic testing. This testing revealed one newborn with two novel SLC22A5 pathogenic variants. In total, 25 newborns were diagnosed with PCD by genetic analyses, for a positive predictive value of 7.91% (25/316) (Table 2). Therefore, during the study period, the incidence of PCD in the selected population was estimated to be 1:8191.

Thirteen distinct SLC22A5 variants were identified, seven of which were included in the designed panel, one previously reported mutation, c.845G > A, was not included in the designed panel, and the remaining five were newly identified pathogenic variants that were recently reported by our team [20]. The most common mutation was c.760C > T, with an allelic frequency of 32% (16/50), followed by c.1400C > G (7/50, 14%), and c.51C > G (7/50, 14%). Four other mutations, c.695C > T, c.1139C > T, c.338G > A, and c.797C > T were also relatively common mutations. These seven mutations accounted for 88% (44/50) of the detected mutant alleles (Table 3).

Biochemical characteristics
The mean C0 concentration at NBS in this cohort was 4.34 ± 1.81 μmol/L. At recall, the mean C0 concentration was increased to 5.40 ± 2.94 μmol/L in the second screening. Of note, six patients (no. 3, 4, 14, 15, 18, and 25) with low C0 levels (2.73–7.35 μmol/L) in the first screening had C0 levels (8.64–14.27 μmol/L) that were above the normal cut-off value in the second screening (Table 2).

Discussion
The sensitivity of NBS for PCD is unsatisfactory because a small proportion of PCD patients are missed using the current MS/MS-based screening approach. Our findings revealed a proportion of cases (24%, 6/25) that
were missed by conventional NBS. Therefore, physicians should note that a normal C0 level during recall does not rule out PCD. Incorporating this second-tier mutation test into the current NBS program would introduce an opportunity to identify missed PCD cases. The high-throughput iPLEX genotyping assay that was used is low-cost (~$3.6/sample) and has a fast turn-around time of 7 h (from DNA preparation to data report), and it was proven to be robust and reliable in the validation. Six PCD patients who would have been missed were successfully identified when we applied the iPLEX assay as a second-tier screening method. Therefore, we clearly demonstrated that incorporating second-tier molecular genetic testing into the current NBS program could increase PCD detection.

The iPLEX assay has several advantages. First, as we demonstrated in our previous work, it is a powerful tool for population-based genetic screening [18, 19].

Table 2  Biochemical and genetic characteristics of patients with PCD

| No | Gender | NC0 levels (μmol/L) | RCD levels (μmol/L) | Screened by MassArray assay | Confirmed by NGS |
|----|--------|---------------------|---------------------|-----------------------------|------------------|
|    |        |                    |                     | Allele 1                   | Allele 2         |
|    |        |                     |                     | c.760C>T                   | c.51C>G          |
| 1  | Male   | 1.96                | 1.73                | c.760C>T                   | c.51C>G          |
| 2  | Female | 2.40                | 1.44                | c.760C>T                   | c.51C>G          |
| 3  | Male   | 5.78                | 10.67               | c.760C>T                   | c.760C>T         |
| 4  | Male   | 5.95                | 8.64                | c.695C>T                   | c.797C>T         |
| 5  | Female | 7.27                | 6.66                | c.760C>T                   | c.797C>T         |
| 6  | Female | 5.58                | 5.59                | c.760C>T                   | c.1400C>G        |
| 7  | Female | 5.34                | 6.02                | c.797C>T                   | c.797C>T         |
| 8  | Female | 1.78                | 1.90                | c.695C>T                   | c.1139C>T        |
| 9  | Male   | 4.34                | 4.45                | c.51C>G                    | c.51C>G          |
| 10 | Female | 4.75                | 4.16                | c.760C>T                   | c.760C>T         |
| 11 | Female | 3.45                | 5.24                | c.760C>T                   | c.1400C>G        |
| 12 | Female | 6.82                | 5.02                | c.760C>T                   | c.1400C>G        |
| 13 | Male   | 2.19                | 2.12                | NF                         | c.822G>A         |
| 14 | Male   | 2.73                | 9.84                | c.51C>G                    | c.1144_1162del   |
| 15 | Male   | 3.00                | 10.81               | c.51C>G                    | c.1400C>G        |
| 16 | Male   | 6.46                | 5.10                | c.695C>T                   | c.1400C>G        |
| 17 | Male   | 3.02                | 1.77                | c.760C>T                   | c.1400C>G        |
| 18 | Female | 6.77                | 10.05               | c.1400C>G                  | c.760C>T         |
| 19 | Female | 2.36                | 1.75                | c.760C>T                   | c.1400C>G        |
| 20 | Female | 3.12                | 2.88                | c.760C>T                   | c.1400C>G        |
| 21 | Male   | 3.64                | 3.80                | c.695C>T                   | c.1139C>T        |
| 22 | Female | 3.56                | 4.31                | c.760C>T                   | c.1139C>T        |
| 23 | Female | 6.27                | 3.43                | c.695C>T                   | c.1139C>T        |
| 24 | Female | 2.70                | 3.46                | c.760C>T                   | c.1139C>T        |
| 25 | Male   | 7.35                | 14.27               | c.338G>A                   | c.338G>A         |

Table 3  Detected SLC22A5 variants and their frequencies

| No | Variants | Alleles | Frequencies (%) |
|----|----------|---------|-----------------|
| 1  | 760C>T   | 16      | 32              |
| 2  | c.1400C>G| 7       | 14              |
| 3  | c.51C>G  | 7       | 14              |
| 4  | c.695C>T | 5       | 10              |
| 5  | c.1139C>T| 4       | 8               |
| 6  | c.797C>T | 3       | 6               |
| 7  | c.338G>A | 2       | 4               |
| 8  | c.845G>A | 1       | 2               |
| 9  | c.394-1G>A| 1      | 2               |
| 10 | c.782_799del| 1 | 2             |
| 11 | c.822G>A| 1       | 2               |
| 12 | c.1144_1162del| 1 | 2            |
| 13 | c.1160A>G| 1       | 2               |

The novel SLC22A5 variants identified by our team are in boldface type.

NCD: free carnitine detected at newborn screening, RCD: C0 retested at recall stage, cutoff value: 8–50 μmol/L.
The novel SLC22A5 variants identified by our team are in boldface type.

NF not found.
screening of suspected PCD, which should provide rapid diagnosis of most PCD patients and help shorten the time to diagnosis. The application of this second-tier testing led to early identification of six patients with PCD (no. 3, 4, 14, 15, 18, and 25), which enabled them to receive timely treatment and prevent the occurrence of adverse symptoms. These six patients would have escaped detection if the new screening algorithm was not implemented, indicating the importance of this second-tier genetic testing for discovering latent PCD patients in the NBS program. However, it is noteworthy that the improvement in sensitivity comes at the expense of increased carrier identification. A previous study in Taiwan used second-tier molecular tests to screen for c.760C > T in 206 newborns with low C0 levels and found 10 carriers, which were excluded due to their normal C0 levels in the second screening [21]. In contrast, our study found that 4% (4/99) of carriers had a second SLC22A5 mutation/variant and were diagnosed with PCD (no. 4, 7, 10, and 14) rather than as carriers, and two of them had normal C0 levels in the second screening. The challenge is how best to use this assay to increase detection and minimise the detection of unaffected carriers that require further genetic analysis. Thus, large-scale studies are needed to optimise the workflow of the second-tier genetic screening and to evaluate the cost-effectiveness of this screening approach. Notably, although the panel with 17 hotspots was designed to detect the majority of SLC22A5 mutations in China, one patient (no. 13) with extremely low C0 levels was missed by our second-tier genetic testing. All predefined panels are faced with this deficiency because the known mutations in a specific population have been less well studied. Due to the extremely low C0 levels of this study subject in the second screening, NGS was performed, and two novel SLC22A5 pathogenic variants were identified. Therefore, further genetic analysis is required when newborns have persistently low C0 levels, but no mutation is found in the second-tier genetic screening.

Based on NBS including second-tier genetic screening, the incidence of PCD in the selected population was estimated at 1:8191. This incidence is higher than that reported in most other regions of China [9, 22, 23]. Although there may be regional differences, our findings suggest that the true incidence of PCD in China might be underestimated. Consistent with many previous studies [24, 25], c.760C > T (p.R254*) was the most frequently occurring mutation in this cohort. This mutation along with two others, c.1400C > G and c.51C > G, had a combined frequency of 60%, confirming that these are hotspot mutations among Chinese populations [24, 26].

This study had some limitations. First, the sole criterion for inclusion was an abnormal PCD NBS result. However, it is important to note that C0 levels in newborns can be affected by the mother because C0 is transported to the foetus via the placenta [6, 12, 27]. Using the current algorithm, a newborn with PCD with a false-negative result of normal C0 levels in the NBS would not be selected for second-tier SLC22A5 mutation analysis. Therefore, it is possible that some PCD cases missed during NBS would not have come to our attention. Utilising a higher C0 cut-off value could reduce the number of missed cases during NBS; however, this may result in an unacceptable percentage of false positives. Balancing these two metrics will be challenging. Second, 193 of the 197 screen-negative newborns were excluded due to normal C0 levels in the second screening, and it is possible that one or more of these 193 newborns classified as screen-negative might have PCD, although the likelihood is very small. However, given that the cost and the fact that the second-tier genetic screening did not detect any SLC22A5 mutations, no further genetic analysis was performed to verify the results. Third, the iPLEX assay can only identify known mutations in the designed assay panel. Our designed panel, with 17 hotspots, can only detect the majority of SLC22A5 mutations in the Chinese population, and untargeted variants will be missed, as demonstrated by the finding of two novel SLC22A5 variants and a previously reported mutation in this study.

Conclusions
In summary, the incidence of PCD is relatively high in Quanzhou, China. Data from this study revealed that 24% (6/25) of PCD cases identified by our genetic screening would have been missed by conventional NBS. The high-throughput iPLEX assay is a powerful tool for PCD genotyping. The incorporation of second-tier genetic screening into the current PCD NBS program could introduce an opportunity to identify missed PCD cases, thereby increasing PCD detection. PCD NBS continues to be a challenge, as newborns with persistently low C0 levels would require combined genetic analyses, and further studies are needed to optimise the workflow of the new screening algorithm and evaluate the cost-effectiveness of this screening approach.

Methods
Study cohort
In an initial evaluation, 20 DBS specimens collected from patients with confirmed PCD were used to assess
the robustness of the iPLEX assay. From January 2017 to December 2018, 204,777 newborns were screened via MS/MS at Quanzhou Maternity and Children’s Hospital; newborns with low C0 levels (C0 < 8 μmol/L, cut-off value: 8–50 μmol/L) were recruited for the study. This study was approved by the Ethical Committee of Quanzhou Maternity and Children’s Hospital. Written informed consent was obtained from the parents of all infants for the collection of DBS samples and the publication of medical data.

Multiplex primary carnitine deficiency assay design and genotyping
PCR and iPLEX extension primers were designed for 17 SLC22A5 mutations using MassArray Assay Design 3.1 software (Agena, San Diego, CA), with amplicon lengths of 80–120 bp and a mass range of 4,500–9,000 Da. The designed primers were run through BLAT and modified when necessary to avoid pseudogene amplification. The designed primers cover nearly all the most common SLC22A5 gene mutation sites, based on the mutation frequencies reported in previous studies [5, 9, 24, 26, 28, 29] and a local mutation database (Additional file 1: Table S1). Genotyping was performed using the MassARRAY platform according to the manufacturer’s instructions.

Screening algorithm and diagnostic evaluation
A second-tier newborn genetic screening targeting 17 SLC22A5 mutations was performed, and the analytical workflow is summarised in Fig. 1. The C0 cut-off value was initially set to the 99.5th (0.05th) percentile in our laboratory but was slightly modified to minimise false-positive and false-negative results. After routine newborn metabolic screening was completed, DBS specimens collected from newborns with low C0 levels were sent for SLC22A5 mutation screening. Newborns with two, one, and no SLC22A5 mutations were defined as screen-positives, screen-carriers, and screen-negatives, respectively. All screen-positives and screen-carriers were recalled and underwent further diagnostic evaluation, including biochemical laboratory tests and genetic analysis. Screen-negatives were also recalled if their C0 levels were persistently low (i.e., below the cut-off in both the first and second screening), even if no mutations were identified, and were referred for diagnostic evaluation. Targeted next-generation sequencing (NGS) using an inherited metabolic disorder panel was performed as previously described [30]. A confirmatory diagnosis was made based on the presence of biallelic pathogenic variants in SLC22A5. Diagnosed patients were treated with L-carnitine supplementation (50–100 mg/kg/d).

![Fig. 1 The analytical workflow of newborn second-tier genetic screening for primary carnitine deficiency (PCD). MS/MS indicates tandem mass spectrometry; NGS: next-generation sequencing; C0: free carnitine; RC0: retested C0 during the recall stage](image-url)
Abbreviations
PCD: Primary carnitine deficiency; OCTN2: Organic cation transporter type 2; MS/MS: Tandem mass spectrometry; NBS: Newborn screening; Co: Free carnitine; DBS: Dried blood spot; NGS: Next-generation sequencing.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13023-021-01785-6.

Additional file1: Table S1. Customized panels based on reported SLC22A5 mutations.

Acknowledgements
We thank all the participants for their help and support. We thank the Hangzhou Genuine Clinical Laboratory (Hangzhou, China) for the professional genetic sequencing and analyzing.

Authors’ contributions
YM Lin performed the data analysis, drafted and revised the manuscript; WF Pang followed the patients and collected the clinical data; QL Fu assisted with data collection, reviewed and revised the manuscript; DM Chen designed and supervised the research study. All authors contributed to the data analysis, revising and approving the final manuscript to be published. All authors read and approved the final manuscript

Funding
This work was funded by the Natural Science Foundation of Fujian province (Grant No. 2020J01130 to Yiming Lin) and the Youth Research Project in the Health System of Fujian Province (Grant No. 2020QNA083 to Yiming Lin).

Availability of data and materials
The datasets used and/or analysed during the current study can be obtained from the corresponding author upon a reasonable request.

Declarations

Ethics approval and consent to participate
This study was approved by the Ethical Committee of Quanzhou Maternity and Children’s Hospital and was performed in accordance with the Declaration of Helsinki. Written informed consent was obtained from the parents of all infants for collection of DBS samples and publication of medical data.

Consent for publication
Consent was obtained from the parents of all patients for publication.

Competing interests
The authors declare that they have no conflicts of interest.

Author details
1 Neonatal Disease Screening Center, Quanzhou Maternity and Children’s Hospital, 700 Fengze Street, Quanzhou 362000, Fujian Province, China. 2 Department of Neonatal Intensive Care Unit, Quanzhou Maternity and Children’s Hospital, 700 Fengze Street, Quanzhou 362000, Fujian Province, China. 3 Zhejiang Biosan Biochemical Technologies Co., Ltd, Hangzhou, China.

Received: 20 January 2021 Accepted: 16 March 2021 Published online: 23 March 2021

References
1. Nezu J, Tamai I, Oku A, Ohashi R, Yabuuchi H, Hashimoto N, et al. Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporter. Nat Genet. 1999;21(1):91–4.
2. Tang NL, Ganapathy V, Wu X, Hui J, Seth P, Yuen PM, et al. Mutations of OCTN2, an organic cation/carnitine transporter, lead to deficient cellular carnitine uptake in primary carnitine deficiency. Hum Mol Genet. 1999;8(8):655–60.
3. Koizumi A, Nozaki J, Ohura T, Kayo T, Wada Y, Nezu J, et al. Genetic epidemiology of the carnitine transporter OCTN2 gene in a Japanese population and phenotypic characterization in Japanese pedigrees with primary systemic carnitine deficiency. Hum Mol Genet. 1999;8(12):2247–54.
4. Magoulas PL, El-Hattab AW. Systemic primary carnitine deficiency: an overview of clinical manifestations, diagnosis, and management. Orphanet J Rare Dis. 2012;7:68.
5. El-Hattab AW, Li FY, Shen J, Powell BR, Bawle EV, Adams DJ, et al. Maternal systemic primary carnitine deficiency uncovered by newborn screening: clinical, biochemical, and molecular aspects. Genet Med. 2010;12(1):19–24.
6. Longo N, Frigieri M, Pasquali M. Carnitine transport and fatty acid oxidation. Biochim Biophys Acta. 2016;1863(10):2422–35.
7. Rasmussen J, Duno M, Lund AM, Steuerwald U, Hansen SH, Joensen HD et al. Increased risk of sudden death in untreated Primary Carnitine Deficiency. J Inherit Metab Dis 2019.
8. Gelinas R, Leach E, Horvath G, Laksmn Z. Molecular autopsy implicates primary carnitine deficiency in sudden unexplained death and reversible short QT syndrome. Can J Cardiol. 2019;35(9):1256 e1251–1256 e1252.
9. Lin Y, Xu H, Zhou D, Hu Z, Zhang C, Hu L et al. Screening 3.4 million newborns for primary carnitine deficiency in Zhejiang Province, China. Clin Chim Acta 2020, 507:199–204.
10. Longo N. Primary carnitine deficiency and newborn screening for disorders of the carnitine cycle. Ann Nutr Metab. 2016;68(Suppl 3):5–9.
11. Grunert SC, Tucci S, Schumann A, Schweindt M, Gramer G, Hoffmann GF et al. Primary carnitine deficiency - diagnosis after heart transplantation: better late than never! Orphanet J Rare Dis 2020, 15(1):87.
12. Lee NC, Tang NL, Chien YH, Chen CA, Lin SJ, Chiu PC, et al. Diagnoses of newborns and mothers with carnitine uptake defects through newborn screening. Mol Genet Metab. 2010;100(1):46–50.
13. Rasmussen J, Hougaaed DM, Sandhu N, Fjællegaard K, Petersen PR, Steuerwald U, et al. Primary carnitine deficiency: is foetal development affected and can newborn screening be improved? JIMD Rep. 2017;36:35–40.
14. Wilson C, Knoll D, de Hora M, Kyle C, Glamuzina E, Webster D. The decision to discontinue screening for carnitine uptake disorder in New Zealand. J Inherit Metab Dis. 2019;42(1):86–92.
15. Lahouchi N, Lodder EM, Mansouri M, Tadros R, Znier L, Adadi N, et al. Exome sequencing identifies primary carnitine deficiency in a family with cardiomyopathy and sudden death. Eur J Hum Genet. 2017;25(6):783–7.
16. Verbeeten KC, Lamhonwah AM, Bulman D, Faghfoury H, Chakraborty P, Tein I, et al. Carnitine uptake defect due to a 5'UTR mutation in a pedigree with false positives and false negatives on Newborn screening. Mol Genet Metab. 2020;129(6):e1251–1256 e1252.
17. Shibbani K, Fahed AC, Al-Shaar L, Arabi M, Nemer G, Bitar F, et al. Primary carnitine deficiency: novel mutations and insights into the cardiac phenotype. Clin Genet. 2014;85(2):127–37.
18. Lin Y, Liu Y, Zhu L, Le K, Shen Y, Yang C, et al. Combining newborn metabolic and genetic screening for neonatal intractable cholestasis caused by citrullinemia. J Inherit Metab Dis. 2020;43(3):467–77.
19. Lin Y, Lin CH, Yin X, Zhu L, Yang J, Shen Y, et al. Newborn screening for spinal muscular atrophy in China using DNA mass spectrometry. Front Genet. 2019;10:1255.
20. Lin W, Wang K, Zheng Z, Chen Y, Fu C, Lin Y, et al. Newborn screening for primary carnitine deficiency in Quanzhou, China. Clin Chim Acta. 2021;512:166–71.
21. Wang LY, Chen NI, Chen PW, Chiang SC, Hwu WL, Lee NC, et al. Newborn screening for citrulline and carnitine uptake defect using second-tier molecular tests. BMC Med Genet. 2013;14:24.
22. Yang Y, Wang L, Wang B, Liu S, Yu B, Wang T. Application of next-generation sequencing following tandem mass spectrometry to expand newborn screening for inborn errors of metabolism: a multicenter study. Front Genet. 2019;10:86.
23. Zhou W, Li H, Huang T, Zhang Y, Wang C, Gu M. Biochemical, molecular, and clinical characterization of patients with primary carnitine deficiency via large-scale newborn screening in Xuzhou area. Front Pediatr. 2019;7:50.
24. Han L, Wang F, Wang Y, Ye J, Qiu W, Zhang H, et al. Analysis of genetic mutations in Chinese patients with systemic primary carnitine deficiency. Eur J Med Genet. 2014;57(10):S71–S.
25. Tang NL, Hwu WL, Chan RT, Law HK, Fung LM, Zhang WM. A founder mutation (R254X) of SLC22A5 (OCTN2) in Chinese primary carnitine deficiency patients. Hum Mutat. 2002;20(3):232.
26. Zhang Y, Li H, Liu J, Yan H, Liu Q, Wei X, et al. Molecular investigation in Chinese patients with primary carnitine deficiency. Mol Genet Genomic Med. 2019;7(9):e901.
27. Rasmussen J, Nielsen OW, Janzen N, Duno M, Gislason H, Kober L, et al. Carnitine levels in 26,462 individuals from the nationwide screening program for primary carnitine deficiency in the Faroe Islands. J Inherit Metab Dis. 2014;37(2):215–22.
28. Dobrowolski SF, McKinney JT, Amat di San Filippo C, Giak Sim K, Wilcken B, Longo N. Validation of dye-binding/high-resolution thermal denaturation for the identification of mutations in the SLC22A5 gene. Hum Mutat. 2005;25(3):306–313.
29. Chen YC, Chien YH, Chen PW, Leung-Sang Tang N, Chiu PC, Hwu WL, et al. Carnitine uptake defect (primary carnitine deficiency): risk in genotype-phenotype correlation. Hum Mutat. 2013;34(4):655.
30. Lin Y, Peng W, Jiang M, Lin C, Lin W, Zheng Z, et al. Clinical, biochemical and genetic analysis of Chinese patients with isobutyryl-CoA dehydrogenase deficiency. Clin Chim Acta. 2018;487:133–8.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.